MICHAELA LIEDTKE

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
    MICHAELA LIEDTKE
    Stanford University School of Medicine, Stanford, USA Electronic address
    Leuk Res 38:1441-5. 2014
  2. pmc Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
    Shira Dinner
    Haematologica 98:1593-9. 2013
  3. pmc The transcription factor encyclopedia
    Dimas Yusuf
    Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Genome Biol 13:R24. 2012
  4. pmc Therapeutic targeting of MLL
    MICHAELA LIEDTKE
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 113:6061-8. 2009
  5. pmc Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
    MICHAELA LIEDTKE
    Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Haematologica 97:30-7. 2012
  6. doi request reprint The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
    Shira Dinner
    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Br J Haematol 161:367-72. 2013
  7. pmc Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Daniel A Pollyea
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Haematologica 98:591-6. 2013
  8. doi request reprint A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma
    Tamara J Dunn
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Br J Haematol 173:253-9. 2016
  9. doi request reprint Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies
    Brandon C Varr
    Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Heart Lung Transplant 31:325-31. 2012
  10. doi request reprint Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
    Rupa Narayan
    a Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Leuk Lymphoma 57:609-15. 2016

Collaborators

  • Bruno C Medeiros
  • Sally Arai
  • Daniel A Pollyea
  • JASON R GOTLIB
  • Ying Hao
  • Quynh Thu Le
  • Ash A Alizadeh
  • Holbrook E Kohrt
  • Tim C P Somervaille
  • Ronald M Witteles
  • Omar Abdel-Wahab
  • Marcia M Bieber
  • Tracy I George
  • Shira Dinner
  • Stanley L Schrier
  • Tamara J Dunn
  • Caroline Berube
  • Dadi Jiang
  • Rupa Narayan
  • Masayuki Iwasaki
  • Samit Patel
  • Richard Lafayette
  • Wesley Witteles
  • Dimas Yusuf
  • Tamara Dunn
  • Brandon C Varr
  • Nicholas C Denko
  • Amato J Giaccia
  • Jacqueline S Garcia
  • Zhifen Yang
  • Steve Coutre
  • Michael H Cardone
  • Muthuraman Alagappan
  • Peter Greenberg
  • Mary Elizabeth M Percival
  • Charles Williamson
  • Rakesh Bam
  • Kathleen Regan
  • Albert C Koong
  • Alex McMillan
  • Maho Niwa
  • Camille Doykan
  • Elizabeth Price
  • Rhonda Hewitt
  • Connor Lynch
  • Parveen Abidi
  • Arvin B Tam
  • Steven E Coutre
  • Michael L Cleary
  • Andrew J Gentles
  • Anosheh Afghahi
  • Dat Ngo
  • Anthony Lam
  • Robert F Hevner
  • Scott Ferrell
  • Jan J Brosens
  • Christopher J Harvey
  • Michelle Vaz
  • Lars Grontved
  • Sylvie Mader
  • Dominique Leprince
  • Carol F Webb
  • Mark W Woodcroft
  • Kelly L Prince
  • Gieri Camenisch
  • Philip H Bradley
  • Mary B Breslin
  • Elizabeth M Simpson
  • Chunyan Zhao
  • Jason Park
  • Mariastella Zannini
  • Warren A Cheung
  • Rumela Chakrabarti
  • Shyam Biswal
  • Christopher T D Dickman
  • Yuriko Mishima
  • Venu Raman
  • Jake M Schnabl
  • Edwin Chen
  • Yunfu Sun
  • Susanne Mandrup
  • Marieke Rozendaal
  • Harini Chakravarthy
  • Bruce E Torbett
  • Kyster K Nanan
  • Marrit Putker
  • Daniel J Peet
  • Miranda S C Wilson
  • Elizabeth Wederell
  • Sekhar P Reddy

Detail Information

Publications17

  1. doi request reprint Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
    MICHAELA LIEDTKE
    Stanford University School of Medicine, Stanford, USA Electronic address
    Leuk Res 38:1441-5. 2014
    ..02). Thirty-day mortality rate was 7.5%. In relapsed or refractory ALL, MEC demonstrated moderate activity, but did not improve survival compared to published salvage chemotherapy regimens. ..
  2. pmc Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
    Shira Dinner
    Haematologica 98:1593-9. 2013
    ..Our data highlight the importance of developing novel treatment approaches for amyloid cardiomyopathy. This trial was registered at www.clinicaltrials.gov (NCT00890552). ..
  3. pmc The transcription factor encyclopedia
    Dimas Yusuf
    Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Genome Biol 13:R24. 2012
    ..TFe aims to rapidly educate scientists about the TFs they encounter through the delivery of succinct summaries written and vetted by experts in the field. TFe is available at http://www.cisreg.ca/tfe...
  4. pmc Therapeutic targeting of MLL
    MICHAELA LIEDTKE
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 113:6061-8. 2009
    ..These advances in our understanding of MLL-related leukemogenesis provide a foundation for ongoing and future efforts to develop novel therapeutic strategies that will hopefully result in better treatment outcomes...
  5. pmc Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
    MICHAELA LIEDTKE
    Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Haematologica 97:30-7. 2012
    ....
  6. doi request reprint The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
    Shira Dinner
    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Br J Haematol 161:367-72. 2013
    ..Evaluation of bone marrow plasma cell infiltration and presence of myeloma associated end organ damage could be clinically useful for prognostication of patients with AL...
  7. pmc Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Daniel A Pollyea
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Haematologica 98:591-6. 2013
    ..In conclusion, a sequential combination of azacitidine plus lenalidomide has clinical activity in older patients with acute myeloid leukemia, and further studies of this combination are underway...
  8. doi request reprint A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma
    Tamara J Dunn
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Br J Haematol 173:253-9. 2016
    ..Pralatrexate, in combination with bortezomib, was generally safe and demonstrated modest activity in relapsed or refractory multiple myeloma. Clinicaltrials.gov identifier: NCT01114282. ..
  9. doi request reprint Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies
    Brandon C Varr
    Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Heart Lung Transplant 31:325-31. 2012
    ..A novel strategy of OHT, followed by light-chain suppressive chemotherapy before autologous hematopoietic stem cell transplant, is feasible for patients with light-chain amyloidosis...
  10. doi request reprint Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
    Rupa Narayan
    a Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Leuk Lymphoma 57:609-15. 2016
    ..The median overall survival (OS) for responders vs non-responders was 9.8 vs 4.0 months, respectively (HR = 0.36, p = 0.016). In conclusion, this combination demonstrated modest clinical activity in this poor risk population...
  11. doi request reprint A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia
    Samit Patel
    Department of Pharmacy, Stanford Hospital, Stanford University Medical Center, Stanford, CA, USA
    Leuk Lymphoma 54:2231-5. 2013
    ..Higher induction mortality observed with doxorubicin substitution in this analysis needs further study...
  12. doi request reprint Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience
    Holbrook E Kohrt
    Department of Medicine, Division of Hematology, Stanford University, Stanford, CA 94305, USA
    Am J Hematol 85:877-81. 2010
    ..3 and 7.6 months, P = 0.36). Despite risk stratification by the European Prognostic Index, our series demonstrates inferior rates of response and survival, illustrating the limited activity of this regimen in our cohort...
  13. doi request reprint Plasma cell leukemia: concepts and management
    MICHAELA LIEDTKE
    Department of Medicine, Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2329, Stanford, CA 94305 5821, USA
    Expert Rev Hematol 3:543-9. 2010
    ....
  14. doi request reprint Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options
    Tamara Dunn
    Stanford University, School of Medicine, Stanford, CA 94027, USA
    Hematology 17:325-8. 2012
    ..Therefore recognizing signs and symptoms of HLH is essential to avoid treatment delay. In our case, high-dose corticosteroids alone were a safe and effective therapy for the mother and fetuses resulting in long-term disease control...
  15. pmc Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response
    Dadi Jiang
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305 USA
    Sci Rep 6:33353. 2016
    ..Our findings suggest that the UPR-modulating activity of doxorubicin may be utilized clinically to target IRE1α-XBP1-dependent tumors such as MM. ..
  16. pmc CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia
    Masayuki Iwasaki
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cell Stem Cell 17:412-21. 2015
    ..Thus, CD93 expression identifies a predominantly cycling, non-quiescent leukemia-initiating cell population in MLL-rearranged AML, providing opportunities for selective targeting and eradication of LSCs...
  17. pmc Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6
    MICHAELA LIEDTKE
    Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
    Blood 116:63-70. 2010
    ..Rather, the AF6 RA1 domain efficiently mediated self-association, suggesting that constitutive MLL self-association is a more common pathogenic mechanism for MLL oncogenesis than indicated by previous studies of rare MLL fusion partners...